Guangdong HEC Pharmaceutical discovers new PD-1/PD-L1 interaction inhibitors
Sep. 19, 2024
Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.